Skip to main content

Table 3 Clinical and demographic characteristics of patients receiving disease-modifying anti-rheumatic treatment with methotrexate or having no disease-modifying anti-rheumatic drug (DMARD) treatment

From: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control

Characteristic Methotrexate treated No DMARD
Patients (n) 19 26
Age (years ± standard deviation) 63.8 ± 14.3 60.8 ± 14.0
Sex (male/female) 5/14 8/18
Disease duration (years ± standard deviation) 13.1 ± 9.6* 8.2 ± 8.3
Rheumatoid factor (+/-) 12/7 14/12
Radiographic data (erosive/non-erosive) 15/4* 10/16
  1. * P < 0.05 as compared with patients without DMARD treatment.